Drug · No ChEMBL mechanism_of_action record for clodronic acid. Clinically a non-nitrogenous bisphosphonate (ATC M05BA02); in the source study the liposomal formulation is used to deplete phagocytic macrophages. Co-agent rolipram resolved separately as CHEMBL63 (phosphodiesterase 4 inhibitor, target CHEMBL2093863, max_phase 2).
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Contusion spinal cord injury
Combined liposomal clodronate and rolipram produced the greatest neuroprotection, axonal sparing and locomotor recovery after contusion SCI.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
Model: Closed articular fracture of the left tibial plateau by controlled compression (10 N pre-load then 20 N/s to fracture, indenter displacement limited to 2.7 mm); right hind limb served as uninjured contralateral control
Intra-articular macrophage depletion did not reduce synovitis or synovial macrophage numbers 7 days after fracture. Depletion of MaFIA mice 2 days before fracture significantly increased synovitis (P = 0.003) and reduced tibial metaphyseal bone mineral density (P = 0.002 in the results text, P = 0.…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
